Global
Cannabidiol alters the epigenome of hormone-dependent prostate cancer cells
This in vitro study analysed the impact of cannabidiol on DU145, PC3, and LNCaP prostate cancer cell lines. The compound caused a concentration-dependent reduction in cell viability, demonstrating additive or synergistic properties alongside targeted and hormonal treatments. Additionally, cannabidiol modified methylation patterns within LNCaP cells and altered gene expression in all models.
- Decreased prostate cancer cell viability in a concentration-dependent manner.
- Exhibited additive or synergistic interactions with targeted and hormonal therapies.
- Modified methylation in LNCaP cells and altered DNMT1 and EZH2 expression across all models.
- The catalytic activity of EZH2 was unaffected, despite changes in its expression across models.
Our view
A result in cultured cells, which cannot be carried over to people. The work used prostate cancer cell lines (DU145, PC3 and LNCaP); no patients and no animals were involved. What is reported is that cannabidiol altered methylation patterns in LNCaP cells and modulated DNMT1 and EZH2 expression, that this was accompanied by transcriptional changes in cell-cycle pathways, and that cell viability fell in a dose-dependent manner, additively or synergistically with targeted and hormonal therapies. The methylation change was shown in LNCaP cells only and is not a feature of prostate cancer in general. A fall in viability is a measurement in a dish, not a therapeutic effect. Work at this stage cannot be treated as evidence that cannabinoids are effective in cancer treatment.
Sources
Get the latest medical cannabis news by email
We send AMI updates and research summaries once a week.
